Sylvia Hartl

Featured in: Favicon

nature.com Favicon

dovepress.com Favicon

ersjournals.com Favicon

resmedjournal.com Favicon

erj.ersjournals.com

Articles

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial - Nature Medicine

Feb 13, 2024 | nature.com | Benjamin Besse |Sylvia Hartl |Patrick M. Forde |Melissa Johnson |Dong-Wan Kim |Boaz E. Aronson | +7 more

AbstractFor patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →